Skip to content

Exploratory Research on a New CART Cell Therapy for Ovarian Cancer

Exploratory Research on a New CART Cell Therapy for Ovarian Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111812
Enrollment
Unknown
Registered
2025-11-06
Start date
2025-11-06
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary patients confirmed by histopathology to have high-grade serous epithelial ovarian cancer (HGSOC)

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Pathological diagnosis: Primary patients confirmed by histopathology to have high-grade serous epithelial ovarian cancer (HGSOC); 2.Specimen source: The specimens were obtained from surgical or biopsy samples at the First Affiliated Hospital of Wenzhou Medical University; 3.Clinical data: The patient has complete clinical and pathological information (including age, FIGO staging, chemotherapy regimen, imaging, and follow-up data, etc.); 4. Specimen Quality: Formalin-fixed, paraffin-embedded (FFPE) tissue specimens are well-preserved and suitable for pathological staining analysis.

Exclusion criteria

Exclusion criteria: 1.Non-high-grade serous ovarian carcinoma subtypes (such as mucinous, endometrioid carcinoma, etc.); 2.Metastatic ovarian cancer or cases where the primary site is unclear; 3.Has received neoadjuvant chemotherapy or targeted therapy; 4.Poor specimen quality (e.g., insufficient tissue, improper fixation, or severe degradation); 5. Cases with missing clinical or pathological data, or incomplete follow-up information.

Design outcomes

Primary

MeasureTime frame
Ovarian cancer tumor markers and the expression levels of specific targets (such as MSLN);CAR transduction efficiency;T cell subset;

Secondary

MeasureTime frame
Objective response rate, ORR;Disease control rate, DCR;

Countries

China

Contacts

Public ContactOu Rongying

The First Affiliated Hospital of Wenzhou Medical University

ourongying@163.com+86 577 5557 8037

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026